fda warning letters compounding semaglutide september 2025 U.S. sends drug advertising to Lilly, Novo, Hims FDA Drug Recalls and Warnings:

The current recommendation is to avoid obtaining compounded versions of semaglutide from a microdosing clinic

Retatrutide is a next-generation investigational peptide that has gained significant attention within the scientific community due to its unique mechanism of action

4,6 A key issue in the physiology of type 2 diabetes (T2DM) is the reduced incretin effect, which mainly results from decreased activity of the primary incretin hormones, GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic peptide)

[The effect of benfothiamine in the therapy of diabetic polyneuropathy]

This decision reflects real-world clinical practice, where GLP-1 analogs are typically added to metformin or other agents rather than prescribed as standalone therapy